immunology

Four white arrows pointing to computer trash can icon
Biotech

Boehringer, Amgen scrap immunology assets, citing low potential

Phase 1 trials of BI's immune modulator and Amgen's ulcerative colitis small molecule have both been terminated.
Darren Incorvaia Apr 14, 2026 4:00am
climbing rock climber

OrbiMed-backed Pinnacle adds $89M for oral peptides

Mar 26, 2026 10:29am
Living cells illustration Cells membrane with nucleus are floating Medical and science concept background 3D render

After $1B fundraise, Xaira breaks silence on AI work

Mar 17, 2026 2:52pm
Sanofi
Favicon Fierce Pharma

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Mar 4, 2026 3:00am
Deal

Boehringer's $500M pact for oral approach to autoimmune disease

Feb 26, 2026 7:00am
A ballpoint pen rests on top of a stack of documents ready for signing

Lilly, Innovent pen $8.8B collab 'beyond traditional licensing'

Feb 9, 2026 6:45am